SCHEMBL1421848

SCHEMBL1421848

CCc1cc(Cl)cc(C(=O)O)n1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HIF1A Q16665 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
MRGPRX4 Q96LA9 4/20 0.40
MCL1 Q07820 1/20 0.39
PPARA Q07869 2/20 0.38
KMO O15229 2/20 0.38
TPMT P51580 1/20 0.38
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
FABP5 Q01469 1/20 0.38
PTGER1 P34995 1/20 0.36
LMNA P02545 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20011025 0.83 GPR35 (0.42) GPR35ALOX15TSHRHIF1AMRGPRX4
SCHEMBL19013381 0.83 ALOX15 (0.42) GPR35ALOX15TSHRHIF1AHCAR2
SCHEMBL3094908 0.81 KDM4E (0.43) GPR35ALOX15TSHRHIF1AHCAR2
SCHEMBL17281038 0.81 KMO (0.45) GPR35ALOX15TSHRHIF1AHCAR2
SCHEMBL744473 0.80 ALOX15 (0.61) GPR35ALOX15TSHRHIF1AHCAR2
SCHEMBL10130004 0.79 NOS3 (0.50) GPR35ALOX15TSHRHIF1AHCAR2
Hydrochloric Acid SCHEMBL28932404 0.78 ALOX15 (0.58) GPR35ALOX15TSHRHIF1AHCAR2
SCHEMBL21609816 0.77 ALOX15 (0.37) GPR35ALOX15TSHRHIF1AMRGPRX4
SCHEMBL17506423 0.77 NOS3 (0.43) TSHRFABP4LMNATDP1ALDH1A1
SCHEMBL24742269 0.75 MCL1 (0.45) GPR35ALOX15TSHRHIF1AHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404679-B2 Pyrrolidine derivatives as NK2 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2013-03-26 US disclosed
US-20120208803-A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS BISSANTZ CATERINA (FR) 2012-08-16 US disclosed
CN-102066321-A Pyrrolidine derivatives as NK2 receptor antagonists HOFFMANN LA ROCHE 2011-05-18 CN disclosed
EP-2297098-A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
WO-2009153179-A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
US-20090312327-A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312327-A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS TACR2, PRLHR, AVPR2 GPR35 404/4885ALOX15 3274/4885TSHR 64/4885
US-20120208803-A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS TACR2, PRLHR, AVPR2 GPR35 404/4885ALOX15 3274/4885TSHR 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.